Rebirth Strongest Tycoon

You can search “Rebirth Strongest Tycoon 妙笔阁novel website (imiaobige.com)” in Baidu to find the latest chapter!

After determining the target, Xia Yu immediately drew a part from the company’s elite, formed a complete acquisition team, and began to collect detailed information about the target.

Many of these elites hired by targeted hunting have worked in capital management companies or venture capital companies in San Francisco or Silicon Valley, and they are very well informed about the venture capital field in recent years.

In just 5 days, the detailed information of Genentech was collected and presented to Xia Yu’s desk.

Genentech is just abbreviation, the company’s full name is United States Genetic Engineering Technology Company.

The company was founded on April 1976, 4 and is currently based in San Francisco.

In the later generation, Genentech can be regarded as the oldest biotechnology company in the United States. In terms of scale and strength, it is second only to Amgen.

Only in the later generation, Genentech was under the revenue of Switzerland Roche Pharmaceuticals Group, which in 1990 acquired 2.1% of Genentech’s equity shares with 60 billion USD.

By 2009, Switzerland Roche Pharmaceuticals Group once again invested about 400 6 1.8 billion USD to acquire the remaining 40% of equity shares.

In other words, by 2009, Genentech was valued at more than 110 billion USD.

Genentech will undoubtedly be extremely brilliant in the future, but now, it is only a young company that has been established for more than three years and has not been listed.

Genentech was able to establish and develop smoothly even with losses. The venture capital company has contributed.

In the beginning, it was a 27-year-old partner of a venture capital firm called Coller Perkins, Robert S 10000 Sen, and a biochemist at the University of California, founder of the field of DNA recombination, 1976 Nobel Prize winner Professor Herb Boyle founded Genentech.

At that time, Robert S 10000 Sen won 100,000 USD of funds from the company, and Professor Herb Boyle put out 2 points of 60,000 USD in savings. In return, Coller Perkins received 25% of equity shares. .

Then, in January 1977, when the funds ran out, a venture capital company named York Capital Company appeared, invested 1 80 USD and won 50,000% of Genentech’s equity shares, and Coller Perkins followed suit. Equity shares savings are maintained at 25%.

Only 9 months after its establishment, Genentech’s valuation has soared from 400,000 USD at first to 300 USD.

But at this time Genentech’s products are still being tested.

In August of 1977, Genentech synthesized a brain hormone-somatostatin. This major breakthrough made Genentech’s reputation boosted and attracted more venture capital’s attention.

By May 1978, Genentech accepted the third venture capital investment with an investment of 5 3 USD, and Conston Capital acquired 90/50,000 of 100 equity shares. These equity shares were all from Herb · Taken out by Professor Boyle.

Because the venture capital industry has only been around for 20 years, the market is not large, and many aspects are not perfect. Venture capital companies have stronger initiative in startups than later generation. Therefore, the investment agreements signed by the other two venture capital companies and later generation The two venture capital companies continued to share the proportion of insured shares. At that time, Genentech’s valuation soared to 2 2 million USD.

In September last year, Genentech was reorganized and planned to go public, and it was already going through the listing approval process.

It’s just that the goal of listing is Nasdaq, because Genentech, a company with low assets, negative profits, and high valuations, can be listed on the Nasdaq in the United States, with greater influence and scale. York stock exchange, Genentech’s current conditions are basically impossible to enter.

According to the data, Genentech now has 4 shareholders, the equity shares are respectively Professor Herb Boyle, the shares ratio is 40%, and the share ratio is 4%, and the share ratio of Coller Perkins is 25%, and York Capital shares The ratio is 25%, and the share ratio of Conston Capital is 100/8.

According to the annual financial report in 1979 last year, Genentech’s total revenue was only 6,000,000 USD. Because of the successful cloning of growth hormone, many research results are shifting from the research and development stage to the approval stage and are ready for production. Therefore, the net profit is negative. Around 2.5 million USD.

But this does not prevent the capital market from having high expectations for Genentech!

So don’t even think about it now, Genentech’s valuation will be very high!

The valuation is high or not, Xia Yu doesn’t care, because no matter how high it is, it cannot go anywhere.

For him, who holds more then 20 billion USD in cash, it is completely trivial!

In addition to the information of Genentech, the survey results also include information about its three venture capital shareholders.

Among them, Coller Perkins has the weakest strength. Founded in 1972, the company manages 4 funds with a capital of less than 50 million USD.

The investment vision of Coller Perkins is not so good. So far, Genentech has the best investment return prospects.

But now Genentech is on the way to go public. If you want to harvest the fruits, you have to wait at least half a year.

If Xia Yu’s Polaris Capital can come up with money that exceeds their psychological expectations, I believe that Coller Perkins will not waste more than half a year waiting for an unknown.

After reading the information, Xia Yu called Peter Lynch to convene the acquisition team to study the specific acquisition plan.

Xia Yu swept across everyone’s faces and set the tone first: “My goal is to acquire the equity shares of Coller Perkins, York Capital, and Conston Capital, and stop Genentech. The company’s listing process.”

“The second step is to acquire as much equity shares as possible in Professor Herb Boyle’s hands on the basis of completely retaining Professor Herb Boyle!”

At this moment, Genentech’s most valuable company is Professor Herb Boyle who won the Nobel Prize, followed by his scientific research team and the drug patents that have been developed, as for other laboratories, production lines, etc. , It is not important at all, you can buy better ones if you have money!

In any company, the most valuable are people.

This point is more obvious in companies with a high proportion of scientific research, and Genentech is still in the early stage of growth, and the value of people is almost concentrated in Professor Herb Boyle.

“Board-Chairman, according to the normal procedure, Genentech will be listed on the Nasdaq in September or October. Now the market generally estimates Genentech between 9 million USD and a little 200000000 million USD. If we In order to acquire equity shares in the hands of three venture capital companies, combined with the temptation of listing, we must invest at least 500 million USD or even a little 3 million USD.”

A middle-aged subordinate of the acquisition team stood up and said.

Xia Yu immediately replied: “Money is not a problem. The company’s initial capital is 200000000 million USD. I can apply for more funds. As long as there is a suitable project, 1 billion USD can be injected.”

“I want to state here that the consortium behind the company has enough strength. In the future investment and acquisitions, the funding issue is not in the scope of consideration!”

As soon as this remark came out, all the sophisticate present were excited and realized that the company they had joined was not as simple as it seemed on the surface.

But isn’t this better?

In an instant, everyone’s sense of belonging to the company greatly increased.

……

“The difficulty now lies in how to convince the three venture capital companies to give up the idea of ​​going public and sell equity shares to us in advance!”

After everyone discussed, Peter Lynch concluded his speech.

“Board-Chairman, now Genentech is already in the process of going public. The sooner the acquisition, the better, so I suggest dividing it into three acquisition groups and proceeding at the same time.”

After speaking, everyone turned their eyes to Xia Yu.

This is exactly what Xia Yu wants. He nodded and said: “Well, there are three acquisition teams, I will be in charge of one, and you will be in charge of one. Who is willing to take the initiative to stand up for the rest?

“I!”

“Board-Chairman, I do!”

“Board-Chairman, I can do it!”

Several people rushed to say.

The corner of Xia Yu’s mouth raised slightly. After asking a few people to explain their ideas, they ordered the one with the best idea to buy the group leader, and the others were assigned to 3 groups, and then the missing manpower reported to Peter Lynch. , The rest of the deployment company comes in.

After that, several meetings were held and the complete acquisition plan and independent action plan were made.

On March 3th, Xia Yu called everyone to gather in the company’s conference room, and after expressing some inspiring ideas, immediately announced the action.

The 3 acquisition teams were dispatched at the same time and moved towards 3 companies.

PS: North America Foundation sets sail, ask for tickets and subscription!